444 related articles for article (PubMed ID: 17457301)
1. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Force T; Krause DS; Van Etten RA
Nat Rev Cancer; 2007 May; 7(5):332-44. PubMed ID: 17457301
[TBL] [Abstract][Full Text] [Related]
2. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Chen MH
Curr Cardiol Rep; 2009 May; 11(3):167-74. PubMed ID: 19379636
[TBL] [Abstract][Full Text] [Related]
3. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
4. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
5. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
6. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
7. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity of targeted therapies.
Kelly RJ; Billemont B; Rixe O
Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
12. [Renal tolerance of targeted therapies].
Thariat J; Janus N; Barrière J; Launay-Vacher V
Bull Cancer; 2012 Mar; 99(3):317-22. PubMed ID: 22146132
[TBL] [Abstract][Full Text] [Related]
13. Reversible cardiomyopathy associated with sunitinib and sorafenib.
Uraizee I; Cheng S; Moslehi J
N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
[No Abstract] [Full Text] [Related]
14. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
15. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
16. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
17. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
18. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Lenihan DJ
J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
[No Abstract] [Full Text] [Related]
19. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
[Next] [New Search]